Trial · NCT03433898
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part I: Maximum Tolerated Dose (MTD) of Ezabenlimab | Part I - ezabenlimab 240 mg | NA | Milligram | ||
| Part I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment) | Part I - ezabenlimab 240 mg | 0 | Participants | ||
| Part II: MTD of the Ezabenlimab Plus BI 754111 Combination Therapy | Part II - ezabenlimab 240 mg + multiple BI 754111 doses | NA | Milligram | ||
| Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment) | Part II - ezabenlimab 240 mg + BI 754111 400 mg | 0 | Participants | ||
| Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment) | Part II - ezabenlimab 240 mg + BI 754111 600 mg | 0 | Participants | ||
| Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment) | Part II - ezabenlimab 240 mg + BI 754111 800 mg | 0 | Participants | ||
Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort A | 4 | Participants | ||
Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort B | 8 | Participants | ||
Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort C | 0 | Participants | ||
Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D | 2 | Participants | ||
| Part III: Duration of Response | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort A | 478.0 | Inter-Quartile Range 99.0 to 484.0 | Days | |
| Part III: Duration of Response | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort B | 148.0 | Inter-Quartile Range 100.0 to NA | Days | |
| Part III: Duration of Response | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort C | 44.0 | Inter-Quartile Range 44.0 to 44.0 | Days | |
| Part III: Duration of Response | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D | 209.0 | Inter-Quartile Range 126.0 to 292.0 | Days | |
| Part III: Number of Patients With Disease Control | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort A | 15 | Participants | ||
| Part III: Number of Patients With Disease Control | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort B | 16 | Participants | ||
| Part III: Number of Patients With Disease Control | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort C | 9 | Participants | ||
| Part III: Number of Patients With Disease Control | Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D | 7 | Participants | ||
| Part I: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator | Part I - ezabenlimab 240 mg | 0 | Participants | ||
| Part II: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator | Part II - ezabenlimab 240 mg + BI 754111 400 mg | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03433898/results